Redwood Group International (RDWD): That's very interesting since Zonda is r...

Reply Private New

Replies (2) Next 10 Prev Next

Send PM Follow Ignore

Followers	2771
Posts	77901
Boards Moderated	1
Alias Born	05/10/2007

The Rainmaker

Re: Myth post# 6711

Friday, 03/14/2008 2:02:32 PM

Friday, March 14, 2008 2:02:32 PM

That's very interesting since Zonda is reverse merging into CLXN shell. Looks like same IR guy reps SIVC and CLXN.
For CLX Investment Company:Gemini Financial Communications, A. Beyer 951-677-8073

March 4, 2008 - 9:42 AM EST

CLX Investment Company Announces Planned Name Change
New Name Expected to Reflect Focus on Launch of Medical Diagnostic Testing Technologies
CLX Investment Company, Inc. (OTCBB: CLXN), which owns 51% of Zonda, Incorporated, a developer and manufacturer of unique diagnostic tests for the medical and non-medical markets, today announced that the Board of Directors has met and determined that a change in the name of the company is warranted. The Board expects to initiate the process of gaining majority shareholder approval for the name change at the soonest practicable date.

The name change is being pursued in order to properly reflect CLX's current focus and its expected future as a leader in the launch of medical diagnostic testing products. CLX is currently preparing to initiate clinical trials for Zonda's HandiLab-C test for Chlamydia as part of the process to achieve FDA clearance for the product. With FDA clearance, CLX will seek to achieve widespread distribution for the HandiLab-C within the U.S., as well as broader distribution into worldwide markets.

In addition to Zonda's chlamydia product, CLX will seek to explore the market potential for Zonda's other point of care diagnostic testing products, including tests for gonorrhea, yeast (Candida) and Group A Strep. The company will also continue to evaluate additional products and technologies for CLX to become involved with as they are presented to the company.

Vera Leonard, chief executive officer of Zonda and CLX, commented, "The name change is expected to be helpful for the company as we operate within the medical diagnostic testing market."

Robert McCoy, Chairman of the CLX Board of Directors, stated, "We look forward to initiating the process of changing the company's name, since it will remove the last vestiges of its previous structure as an investment fund. Ms. Leonard and the rest of the management team are squarely focused on the medical diagnostic testing market, and we believe the new name will be a helpful for them to pursue the company's goals."

Ms. Leonard recently participated in a question and answer feature that has been posted to the CLX website at http://www.clxinvestments.com/othermedia.php, and a link to the interview has also been added to the company's profile on the home page of Equity Digest at www.equitydigest.com.

The question and answer feature includes a detailed discussion by Ms. Leonard of the estimated market potential for Zonda's rapid point of care diagnostic test for chlamydia.

To sign up to receive information by email directly from CLX Investment Company when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.php.

About CLX Investment Company

CLX Investment Company (www.clxinvestments.com) holds a 51% equity interest in Zonda, Inc. CLX has also invested, and holds a common stock position, in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments' control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Contacts:
For CLX Investment Company:
Gemini Financial Communications
A. Beyer
951-677-8073
Email Contact

CLX Investment Company Announces Selection of Contract Research Organization (CRO) for Clinical Trials on Zonda's Rapid Point of Care Test for Chlamydia
CLX Investment Company, Inc. (OTCBB: CLXN), which owns 51% of Zonda, Incorporated, a developer and manufacturer of unique diagnostic tests for the medical and non-medical markets, today announced that the company has selected Trial Care International, LLC (TCI) to serve as Contract Research Organization (CRO) for the clinical trials for Zonda's rapid point of care test for chlamydia.

2008-The Rainmakers Moneymakers. stock symbol RAIN
http://investorshub.advfn.com/boards/board.asp?board_id=11575